Market Overview

UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01

Share:
Related ACRX
UPDATE: AcelRX Pharma Says 'We have successfully transitioned ARX-04 into late-stage development, defined the regulatory pathway for ARX-04 and Zalviso in the U.S.'
Earnings Scheduled For March 7, 2016
AcelRx Pharmaceuticals' (ACRX) CEO Howie Rosen on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Monday, Jefferies analyst Corey Davis initiated coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and $8.00 price target.

In the report, Davis noted, “We expect FDA approval of ACRX's lead product candidate, ARX-01 (a novel sufentanil nanotab PCA system), in 2014 given the solid body of data from Ph2/initial Ph3 success. We see a clear market opportunity for ARX-01 given the current standard of care for post-op pain control is fraught with drawbacks. We forecast $400M peak potential and little threat of generics. Pipeline and partnerships represent upside to our numbers/valuation.”

AcelRx Pharmaceuticals closed on Friday at $4.90.

Latest Ratings for ACRX

DateFirmActionFromTo
May 2016H.C. WainwrightMaintainsBuy
Oct 2015JefferiesAssumesBuy
Sep 2015H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for ACRX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Analyst Ratings

 

Related Articles (ACRX)

View Comments and Join the Discussion!